Portal de Periódicos da CAPES

Characterization of thrombosis risk in ambulatory patients with cancer: results of the observational, prospective, multicenter CARTAGO study

2024; AlphaMed Press; Linguagem: Inglês

10.1093/oncolo/oyae334

1549-490X

Javier Trujillo‐Santos, Ignacio Escobar, Mercedes Salgado Fernández, António Araújo, Eva Martínez de Castro, Raquel Molina, V.E. Castellón Rubio, Pere Pascual i Domènech, Enrique Gallardo, Esteve Colomé, Ferrán Torres, José Carlos Benítez, Rut Porta Balanyà, Miriam Lobo, Mariana Malheiro, Carme Font, Elena Brozos-Vázquez, Fernando Garicano, Víctor Sapena, Ana Lúcia Costa, A. Martins, Pablo Cerezuela, Sara Agraso, Geòrgia Anguera, Maite Antonio, David Arias Ron, M. Biosca, Ana Blasco, Anna Bustins, Diego Cacho, Núria Calvo, Begoña Campos, Marta Carmona, Elena Cillán, Carmen Díaz‐Pedroche, Paula Espinosa Olarte, F. Navarro Expósito, Isaura Fernández, Lourdes Fernández-Franco, Tomeu Fullana, Silvia García Adrián, Javier García‐Sánchez, Sandra Giménez, Irene González-Cebrián, Manuel González-Moya, Clara Lucía Gozálvez, David Gutiérrez-Abad, Y. Lage, Rosa López, María Luisa Limón, Raquel Luque, Agustín Hernández, Evelin Horváth, Rosa López, Ismael Macías, Montse Mangas, Pascual Marco, Edelmira Martí, Purificación Martínez-del-Prado, Maria Masvidal, Marina Meri-Abad, Marta Merino, Y. de Miguel, Santiago Moragón, Daniela Morello, Berta Obispo, Montse Pàmpols, Pedro Pérez‐Segura, Beatriz de Rivas, Alberto Rodrigo, Silverio Ros, Araceli Sabino-Álvarez, Diego Salgado, Raúl de Pablo, Lucía Teijeira, María Valero-Arbizu, Francisca Vázquez, José Carlos Villa, Paula M. Alves, Júlia Amorim, Anabela Barros, Carolina Carvalho, Nuno Couto, Ana Rita Garcia, Vitória Gemas, Beatriz Gosálbez, Hélder Mansinho, Jorge Martinez, Mafalda Peres, Antonio Pinto, Catarina Pulido, Ana Raimundo, Maria João Ribeiro,

Acute Myocardial Infarction Research

Abstract Background Venous thromboembolism (VTE) is one of the leading causes of death in patients with cancer. Currently, there is a need to develop an easily applicable risk model that can identify patients who will benefit from receiving primary thromboprophylaxis to reduce the incidence of VTE. Patients and methods This was a non-interventional, multicenter, observational, prospective study carried out in 62 Oncology and Hematology services in Spain and Portugal between January 2018 and December 2019. The main objective of the CARTAGO study was to develop a predictive model within a competitive risk framework to assess the risk of VTE in patients with cancer undergoing chemotherapy, biological, or hormonal treatment. Results A total of 1596 patients were analyzed. VTE events occurred in 124 (8%) during the 6-month follow-up period (42% of deep vein thrombosis [DVT], 48% of pulmonary embolism [PE], and 10% of both DVT and PE). Four variables were selected for the multivariate predictive model to determine the risk of VTE (tumor type, D-dimer, compression of a vessel by the tumor, and leukocyte count). The 4 variables were associated with an increased risk of VTE (C-statistic, 0.646 [95%CI, 0.620-0.673]). The most significant variables in the internal validation with bootstrapping were the “very high risk” tumors (hazard ratio [HR] 2.032; 95%CI, 1.287-3.211). Conclusion The CARTAGO model predicts the VTE risk in patients with cancer receiving anticancer therapy in an outpatient setting. This model can easily aid in identifying ambulatory patients who would probably benefit from primary thromboprophylaxis.